XW01348
Introduction Subcutaneous Tissue to New Technology Group 8 with Teclistamab Antineoplastic, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 1 Subcutaneous Tissue |
| Approach | 3 Percutaneous |
| Device | 4 Teclistamab Antineoplastic |
| Qualifier | 8 New Technology Group 8 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Subcutaneous Tissue
Subcutaneous tissue is the fatty layer beneath the dermis that houses blood vessels, nerve endings, and connective tissue, and it serves as a common depot for sustained-release or systemically absorbed substances. Introduction procedures coded here under New Technology involve placing a novel agent into this layer specifically, distinguishing it from superficial skin application or injection into deeper muscle. Because subcutaneous tissue has variable thickness and vascularity depending on body location, absorption characteristics of the introduced substance can differ by site, which may influence dosing and monitoring. This code applies when the substance itself represents an advanced or newly approved technology, such as a novel biologic, rather than a conventional medication already captured under standard Administration section codes.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Teclistamab Antineoplastic
Teclistamab is a bispecific T-cell engaging antibody for relapsed or refractory multiple myeloma that binds BCMA on plasma cells and CD3 on T cells, prompting immune-mediated tumor cell killing. It shares its BCMA target and general mechanism with elranatamab but is a distinct approved product, and it differs from talquetamab, which targets GPRC5D instead, making the specific antigen bound the key distinguishing feature among these myeloma agents.
Qualifier: New Technology Group 8
Group 8 identifies technologies added to the New Technology section for the 2021-2022 update cycle, tying a given code to that specific approval year. The underlying substance, device, or technique is defined by the other six axis positions, not by the group number itself. Because group numbers simply track chronology, Group 8 differs from Group 7 and Group 9 only in when CMS granted the technology separate recognition.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.